OMS721 (phase 2) **Lectin Pathway Initiation Alternative Pathway Initiation** C3 MBL MASP **Spontaneous Formation** C2 C4 (C3(H2O)(Bb) C4b OC4a OC2b C3b C4b Bikaciomab (preclinical) CP C3 Convertase AP C3 Convertase Lampalizumab (phase 3) NM9401 (preclinical) AMY-201 (prelinical) Compstain Derivatives: C3b CP40 (preclinical) APL-1 (phase 1) OC3a APL-2 (phase 2) C5 C4b C3b C3b C3b ○C5a CP C5 Convertase AP C5 Convertase C5b Neutrazumab (preclinical) Eculizumab (approved) NOX-D19 (preclinical) Pexeculizumab (phase 3) NOX-D20 (preclinical) LFG316 (phase 2) NOX-D21 (preclinical) ALXN1210 (preclinical) ALXN550 (preclinical) IFX-1 (phase 2) Coversin (phase 1) SOBI002 (phase 1)

RA101348 (preclinical)

ARC1905 (phase 2)